NASDAQ:CVAC - CureVac Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $58.33
  • Forecasted Upside: -28.28 %
  • Number of Analysts: 4
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$81.33
▼ -2.23 (-2.67%)
1 month | 3 months | 12 months
Get New CureVac Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CVAC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CVAC

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$58.33
▼ -28.28% Downside Potential
This price target is based on 4 analysts offering 12 month price targets for CureVac in the last 3 months. The average price target is $58.33, with a high forecast of $70.00 and a low forecast of $47.00. The average price target represents a -28.28% upside from the last price of $81.33.
Hold
The current consensus among 4 investment analysts is to hold stock in CureVac.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/11/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/10/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/7/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
12/4/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
2/2/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
3/4/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/10/2020Credit Suisse GroupDowngradeNeutral ➝ Underperform$50.00 ➝ $47.00High
i
11/17/2020Berenberg BankReiterated RatingBuyLow
i
9/8/2020Bank of AmericaInitiated CoverageBuy$70.00High
i
9/8/2020Jefferies Financial GroupInitiated CoverageHold$58.00High
i
9/8/2020Credit Suisse GroupInitiated CoverageNeutral$68.00High
i
(Data available from 3/4/2016 forward)
CureVac logo
CureVac N.V., a clinical-stage biopharmaceutical company, engages in developing various transformative medicines based on messenger ribonucleic acid (mRNA). Its lead proprietary programs include CV8102 that is in a Phase 1 dose escalating clinical trials for four types of cancers as a monotherapy and in combination with anti-PD-1; and CV7202, which is in a Phase 1 clinical trials as a vaccine candidate against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase 1 clinical trial. The company's partnered programs comprise BI1361849, a therapeutic vaccine candidate that is in a Phase 1/2 clinical trials to elicit antigen-specific immune responses against tumor-associated antigens frequently overexpressed in patients with non-small cell lung cancer; Cas9 mRNA constructs for use in gene editing therapeutics; mRNA based novel therapeutic antibodies; prophylactic vaccines to prevent picornaviruses, influenza, malaria, and rotavirus; and programs against SARS-CoV-2, Lassa virus, and yellow fever. It has strategic partnerships with Genmab, Arcturus, Acuitas, CRISPR Therapeutics, Boehringer Ingelheim, GlaxoSmithKline, the Bill & Melinda Gates Foundation, CEPI, Tesla Grohmann, and others, as well as a collaboration with the U.K. Government to develop and manufacture potential vaccine candidates against SARS-CoV-2 variants. The company was founded in 2000 and is headquartered in Tübingen, Germany.
Read More

Today's Range

Now: $81.33
$79.60
$87.20

50 Day Range

MA: $103.29
$83.56
$126.29

52 Week Range

Now: $81.33
$36.15
$151.80

Volume

1,309,237 shs

Average Volume

827,028 shs

Market Capitalization

$15.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of CureVac?

The following Wall Street analysts have issued research reports on CureVac in the last year: Bank of America Co., Berenberg Bank, Credit Suisse Group AG, Jefferies Financial Group Inc., and Zacks Investment Research.
View the latest analyst ratings for CVAC.

What is the current price target for CureVac?

3 Wall Street analysts have set twelve-month price targets for CureVac in the last year. Their average twelve-month price target is $58.33, suggesting a possible downside of 28.3%. Bank of America Co. has the highest price target set, predicting CVAC will reach $70.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $47.00 for CureVac in the next year.
View the latest price targets for CVAC.

What is the current consensus analyst rating for CureVac?

CureVac currently has 1 sell rating, 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CVAC, but not buy more shares or sell existing shares.
View the latest ratings for CVAC.

What other companies compete with CureVac?

How do I contact CureVac's investor relations team?

CureVac's physical mailing address is PAUL-EHRLICH-STRABE 15 TUBINGEN, BADEN-WURTTEMBERG 2M, 72076. The company's listed phone number is 49-70-71988-30 and its investor relations email address is [email protected] The official website for CureVac is www.curevac.com.